AtriCure (NASDAQ: ATRC) reported Q1 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $56.06 million.

“Our growth in the first quarter is a testament of our team’s strong execution and unwavering dedication despite continued COVID headwinds,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “As we navigate toward a return to normalcy, I am confident that we are extremely well positioned for the future with our pathway of growth catalysts and the realization of these opportunities underway, beginning with CONVERGE.”

GUIDANCE:

AtriCure sees FY2021 EPS of ($1.15), versus the consensus of ($1.16). AtriCure sees FY2021 revenue of $252-256 million, versus the consensus of $250.29 million.

Full year 2021 revenue is now projected to be approximately $252 million to $256 million. As with previous guidance, continued uncertainty relating to the dynamic environment with the COVID-19 pandemic could materially impact this projection. Additionally, the Company is maintaining guidance for full year 2021 adjusted EBITDA loss of approximately $10 million and adjusted loss per share of $1.15.

For earnings history and earnings-related data on AtriCure (ATRC) click here.